CollPlant Biotechnologies Ltd. (CLGN)

Market Cap	5.85M -71.9%
Revenue (ttm)	2.37M +360.4%
Net Income	-11.49M
EPS	-0.94
Shares Out	14.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,312
Open	0.4116
Previous Close	0.4264
Day's Range	0.4050 - 0.4116
52-Week Range	0.2711 - 4.9800
Beta	0.64
Analysts	Hold
Price Target	11.12 (+2,639.59%)
Earnings Date	Aug 19, 2026

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue mat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 39
• Stock Exchange: NASDAQ
• Ticker Symbol: CLGN
• Website: https://collplant.com

Financial Performance

In 2025, CollPlant Biotechnologies's revenue was $2.37 million, an increase of 360.39% compared to the previous year's $515,000. Losses were -$11.49 million, -30.83% less than in 2024.

Analyst Summary

According to one analyst, the rating for CLGN stock is "Hold" and the 12-month stock price target is $11.12.

Price Target

$11.12

(2,639.59% upside)

Analyst Consensus: Hold